ストックスクリーナーアプリを入手
109.93
0.20%
-0.215
アフターアワーズ：
109.75
-0.18
-0.16%
前日終値:
$110.14
開ける：
$109.3
24時間の取引高:
557.89K
Relative Volume:
0.51
時価総額：
$27.58B
収益：
$3.53B
当期純損益:
$-632.54M
株価収益率:
-41.80
EPS:
-2.6296
ネットキャッシュフロー:
$-588.89M
1週間 パフォーマンス:
+3.83%
1か月 パフォーマンス:
-5.22%
6か月 パフォーマンス:
-0.86%
1年 パフォーマンス:
-8.40%
1日の値動き範囲:
$108.82
$112.24
1週間の範囲:
$105.41
$112.24
52週間の値動き範囲:
$81.20
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
109.93 | 27.64B | 3.53B | -632.54M | -588.89M | -2.6296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.64 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | アップグレード | Goldman | Neutral → Buy |
| 2025-06-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-05-29 | 開始されました | Goldman | Neutral |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-01-10 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-11-19 | 開始されました | Berenberg | Buy |
| 2024-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-08 | アップグレード | Goldman | Neutral → Buy |
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
Moderna, Coinbase, And Global Payments Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio? - Benzinga
BioNTech’s New HIV Antibody Trial Adds Depth to BNTX’s Long-Term Pipeline Story - TipRanks
BioNTech SE (BNTX) Rallying on Solid Oncology Strategy - Finviz
BioNTech's Strategic Pivot: Key Catalysts on the 2026 Horizon () - aktiencheck.de
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data - The Globe and Mail
BioNTech (NASDAQ:BNTX) Lowered to Market Perform Rating by Leerink Partners - Defense World
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings? - Finviz
Leerink downgrades BioNTech to “market perform” after 24% share rally - Investing.com
Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer - TipRanks
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? - Finviz
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline - Finviz
BioNTech SE (BNTX): A Bull Case Theory - Finviz
2 Biotech Stocks Set to Rebound in 2026 - Finviz
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch - TipRanks
BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX - TipRanks
BioNTech SE Sponsored ADR $BNTX Holdings Boosted by Lbp Am Sa - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Sector Gamma AS Has $2.74 Million Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Baillie Gifford & Co. Lowers Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial - TipRanks
BioNTech Shares Gain Momentum on Regulatory and Analyst Support () - aktiencheck.de
BNTX Stock Today: January 23 momentum after six-month high, 2026 catalysts - Meyka
BioNTech (BNTX) soars 11.8%: Is further upside left in the stock? - MSN
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Nasdaq
BioNTech (NASDAQ:BNTX) Trading 7.5% HigherHere's Why - MarketBeat
BioNTech’s BNT142 Trial Termination: What It Means for the Oncology Pipeline and Investors - TipRanks
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - yourwyominglink.com
What to Expect From Pfizer's Non-Oncology Business in Q4? - The Globe and Mail
BioNTech's Strategic Pivot: A Deep Dive into Its Expanding Oncology Pipeline () - aktiencheck.de
Goldman Sachs upgrades BioNTech stock to Buy on oncology potential - Investing.com
SG Americas Securities LLC Sells 69,726 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It - Chartmill
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan - Yahoo Finance
McDonald’s Upgraded, Netflix Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial - TipRanks
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - Finviz
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
3.57%
1.83%
大文字化:
|
ボリューム (24 時間):